Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

VERABullishIndustry Newsnews

High materiality9/10

VERA poised for FDA decision; ORIGIN 3 data support atacicept IgAN approval

Jul 6, 2026, 12:01 PM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Regulatory catalysts (FDA decision) and strong ORIGIN 3 data provide tangible upside; near-term milestones and competitive context (Novartis) create directional risk-reward favorable to upside.

AI summary

What happened, with direct paths to the underlying reporting

VERA Therapeutics faces a pivotal FDA decision on atacicept for IgA nephropathy on July 7. ORIGIN 3 data show meaningful proteinuria reductions, reinforcing a BLA path, with eGFR results moved up to Q3 2026 and a potential sBLA in Q4 2026. Competitor Novartis’ ALIGN results maintain competitive pressure in the IgAN landscape, influencing valuation and timing.

FDA decision on atacicept for IgAN due July 7; accelerated approval pursued.
ORIGIN 3 shows 46% UPCR reduction; 42% vs placebo at week 36.
eGFR plan moved to Q3 2026; sBLA for full approval targeted Q4 2026.
Novartis remains competitor; traditional approval timing anticipated in 2026.
Vera stock up ~30% over the past month.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

VERA poised for FDA decision; ORIGIN 3 data support atacicept IgAN approval

FDA Fast-Tracks Vera's At-Home Kidney Drug

Vera shares skyrocket as kidney disease drug succeeds in late-stage trial

Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years